EHAB250117C10000
- 0.10
- 0.000.00%
Enhabit Newsroom
Cautious Hold Rating for Enhabit Amid Court Ruling and Acquisition Uncertainties
Enhabit Analyst Ratings
Jefferies Upgrades Enhabit(EHAB.US) to Buy Rating, Raises Target Price to $9.5
Enhabit, Inc.: Operational Stability Amid Growth Challenges Leads to Hold Rating
Enhabit Analyst Ratings
Leerink Partners Reiterates Market Perform on Enhabit, Lowers Price Target to $8
Oppenheimer Keeps Their Hold Rating on Enhabit, Inc (EHAB)
TD Cowen Maintains Enhabit(EHAB.US) With Hold Rating, Maintains Target Price $8
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
Enhabit, Inc.: Mixed Q3 Results and Lowered 2024 Guidance Justify Hold Rating
TD Cowen Maintains Enhabit(EHAB.US) With Hold Rating, Maintains Target Price $8
Maintaining Hold on Enhabit, Inc.: Weighing Operational Gains Against Rate Headwinds and Strategic Risks
TD Cowen Sticks to Their Hold Rating for Enhabit, Inc (EHAB)
Enhabit Analyst Ratings
B of A Securities Maintains Underperform on Enhabit, Lowers Price Target to $8
Leerink Partners: Upgraded the Enhabit (EHAB.US) rating from lower than the market to a consistent market rating, with a target price of $8.50.
Enhabit Analyst Ratings
Leerink Partners Upgrades Enhabit to Market Perform From Underperform, Price Target Is $8.50
Hold Rating on Enhabit, Inc. Maintained Amid EBITDA Beat and Ongoing Uncertainties
UBS Trims Price Target on Enhabit to $9 From $10, Keeps Neutral Rating